Results for tag: "Beta Secretase Inhibitor"

The Beta Secretase Inhibitor market is a subset of the larger Alzheimer's Disease Drugs market. Beta Secretase Inhibitors are drugs that target the beta-secretase enzyme, which is involved in the production of amyloid-beta peptides, which are believed to be a major cause of Alzheimer's Disease. These drugs are designed to reduce the production of amyloid-beta peptides, thus slowing the progression of Alzheimer's Disease. The Beta Secretase Inhibitor market is a relatively new market, with the first drug approved in 2019. Since then, several other drugs have been approved, and many more are in development. Companies in the Beta Secretase Inhibitor market include Biogen, Eisai, Merck, and Roche. Show Less Read more